👤 Arjan Bouman

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
2
Articles
2
Name variants
Also published as: Arianne Bouman,
articles
Jordy Dekker, Rachel Schot, Kimberly A Aldinger +87 more · 2025 · American journal of human genetics · Elsevier · added 2026-04-24
Jordy Dekker, Rachel Schot, Kimberly A Aldinger, David B Everman, Camerun Washington, Julie R Jones, Jennifer A Sullivan, Rebecca C Spillmann, Vandana Shashi, Antonio Vitobello, Anne-Sophie Denommé-Pichon, Anne-Laure Mosca-Boidron, Laurence Perrin, Stéphane Auvin, Maha S Zaki, Joseph G Gleeson, Naomi Meave, Cassidy Wallace, Sophie Nambot, Julian Delanne, Sarah M Ruggiero, Ingo Helbig, Mark P Fitzgerald, Richard J Leventer, Dorothy K Grange, Emanuela Argilli, Elliott H Sherr, Supraja Prakash, Derek E Neilson, Francesco Nicita, Antonella Sferra, Enrico S Bertini, Chiara Aiello, Knut Brockmann, Alexander B Kuranov, Silke Kaulfuss, Sulman Basit, Majed Alluqmani, Ahmad Almatrafi, Jan M Friedman, Colleen Guimond, Faruq Mohammed, Pooja Sharma, Divya Goel, Thomas Wirth, Mathieu Anheim, Paulina Bahena, Asuman Koparir, Konstantinos Kolokotronis, Barbara Vona, Thomas Haaf, Erdmute Kunstmann, Reza Maroofian, Henrike L Sczakiel, Felix Boschann, Mala Misra-Isrie, Raymond J Louie, Elliot S Stolerman, Pedro A Sanchez-Lara, Sandra Mergler, Renske Oegema, Yuri A Zarate, Ariana Kariminejad, Homa Tajsharghi, Shimriet Zeidler, Anneke J A Kievit, Arjan Bouman, Gerarda Cappuccio, Nicola Brunetti-Pierri, Kyra E Stuurman, Dayna Morel Swols, Mustafa Tekin, Jariya Upadia, Donna M Martin, Daniel Craven, Susan M Hiatt, Laura A van de Pol, Felice D'Arco, Henri Margot, Martina Wilke, Soheil Yousefi, Tahsin Stefan Barakat, Monique M van Veghel-Plandsoen, Eleonora Aronica, Jasper Anink, Stephen L Rogers, Kevin C Slep, Dan Doherty, William B Dobyns, Grazia M S Mancini Show less
Microtubule-actin cross-linking factor 1 (MACF1) is a large protein of the spectraplakin family, which is essential for brain development. MACF1 interacts with microtubules through the growth arrest-s Show more
Microtubule-actin cross-linking factor 1 (MACF1) is a large protein of the spectraplakin family, which is essential for brain development. MACF1 interacts with microtubules through the growth arrest-specific 2 (Gas2)-related (GAR) domain. Heterozygous MACF1 missense variants affecting the zinc-binding residues in this domain result in a distinctive cortical and brain stem malformation. Evidence for other MACF1-associated disorders is still limited. Here, we present a cohort of 45 individuals with heterozygous or bi-allelic MACF1 variants to explore the phenotypic spectrum and assess possible pathogenic relevance. We observe that de novo heterozygous missense variants in the EF-hand domains also result in distinctive brain malformation and provide experimental evidence that variants in the EF-hand/GAR module increase microtubule binding, suggestive of a toxic gain of function. Notably, no phenotype-genotype correlation was possible for the remaining heterozygous variants in other domains. A clinical review of eight families with bi-allelic variants reveals a possible complex neurodevelopmental syndrome of the central and peripheral nervous systems. In these individuals, bi-allelic variants mostly affect the Plakin domain. Furthermore, RNA sequencing and chromatin immunoprecipitation (ChIP) analyses of human fetal brain tissue reveal five MACF1 isoforms with region-specific expression, differing in their exon 1 transcription start sites but splicing to a common exon 2. This differential expression explains the frontal-predominant lissencephaly in an individual with a homozygous stop-gain in exon 1 (MACF1-204: c.70C>T [p.Arg24∗]), as this isoform is preferentially expressed in the frontal cortex. We conclude that MACF1-related disorders are strictly linked to domain function and the level of transcript expression, explaining the observed wide clinical heterogeneity. Show less
no PDF DOI: 10.1016/j.ajhg.2025.08.010
MACF1
Arianne Bouman, Romy N Bouwmeester, Leo A van Vlimmeren +7 more · 2023 · American journal of medical genetics. Part A · Wiley · added 2026-04-24
The Koolen-de Vries syndrome (KdVS) is a multisystem disorder characterized by developmental delay, intellectual disability, characteristic facial features, epilepsy, cardiovascular and urogenital mal Show more
The Koolen-de Vries syndrome (KdVS) is a multisystem disorder characterized by developmental delay, intellectual disability, characteristic facial features, epilepsy, cardiovascular and urogenital malformations, and various musculoskeletal disorders. Scoliosis is a common feature. The aim of this study is to fill the gap in the current knowledge about scoliosis in individuals with KdVS and to provide recommendations for management and follow-up. In total, 54 individuals with KdVS were included in the study, with a mean age of 13.6 years (range 1.9-38.8 years). Spine radiographs, MR scans, and corresponding radiology reports were analyzed retrospectively for scoliosis and additional anomalies. The presence of scoliosis-related clinical conditions was assessed in participants' medical records and by use of a parent survey. Scoliosis was present in 56% of the participants (30/54) with a mean age of onset of 10.6 years and curve progression during the growth spurt. Prevalence at age 6, 10, and 18 years was, respectively, 9%, 41%, and 65%. Most participants were diagnosed with a single curve (13/24, 54%), of which five participants had a long C-curve type scoliosis. No significant risk factors for development of scoliosis could be identified. Severity was mostly classified as mild, although 29% (7/24) of the curves were larger than 30° at last follow-up. Bracing therapy was received in 13% (7/54), and surgical spinal fusion was warranted in 6% (3/54). Remarkably, participants with scoliosis received less often physical therapy compared to participants without scoliosis (P = 0.002). Scoliosis in individuals with KdVS should be closely monitored and radiologic screening for scoliosis and vertebrae abnormalities is recommended at diagnosis of KdVS, and the age of 10 and 18 years. Show less
no PDF DOI: 10.1002/ajmg.a.63334
KANSL1